Latest news

• Lilly’s donanemab shows promise in early symptomatic Alzheimer's comparator study

  Eli Lilly’s (Lilly) donanemab met all primary and secondary endpoints for the six-month primary outcome analysis of the phase 3 TRAILBLAZER-ALZ 4 study, the company announced, providing the ... In August, Lilly announced that the US Food and Drug

• Lilly restructures in preparation for Alzheimer’s drug launch

  Biogen’s Aduhelm and Lilly’s donanemab are the first new drugs for more than two decades in the therapy area, but they are not without controversy. ... Lilly’s donanemab is not far behind the frontrunner, with the company announcing its intention

• Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial

  Eli Lilly and Banner Alzheimer’s Institute have signed a strategic research collaboration to conduct a phase 3 prevention trial of donanemab. ... In June, the US Food and Drug Administration (FDA) Lilly’s donanemab a breakthrough therapy designation

• Breakthrough therapy designated for Lilly’s investigational Alzheimer’s drug donanemab

  The US Food and Drug Administration (FDA) has granted Eli Lilly’s investigational Alzheimer’s disease drug donanemab a breakthrough therapy designation (BTD). ... Following this, Lilly reported that although secondary outcomes within this trial

• Lilly to expand donanemab study in a bid for approval in Alzheimer’s disease

  Eli Lilly has revealed expanded findings from a phase 2 trial of its potential Alzheimer’s disease treatment donanemab, and announced plans to expand the clinical programme for the drug in ... Donanemab has the potential to become a very important